Reports Q2 revenue $1.03B, consensus $1.01B. “I am proud of the progress the Catalent team made in our second quarter and our ongoing momentum, including strong non-COVID sequential revenue growth in both the Biologics and PCH segments. We also continued to invest in our operational improvement initiatives and areas of high growth,” said Alessandro Maselli, president and CEO of Catalent. “Our commitment to providing customers with premium development and manufacturing solutions is our north star and our recently announced transaction with Novo Holdings is further proof of that. With the benefit of Novo Holdings’ expanded resources, we will be able to accelerate investment in our business and enhance key offerings for current and prospective pharma and biotech customers. Indeed, we remain focused on continuing to serve our valued customers, as we always have.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTLT:
- Options Volatility and Implied Earnings Moves Today, February 09, 2024
- Catalent Inc (CTLT) Q2 Earnings Cheat Sheet
- Novo Nordisk price target raised to $135 from $115 at TD Cowen
- Catalent downgraded to Sector Perform from Outperform at RBC Capital
- Catalent Announces Strategic Merger Agreement with Novo Holdings